Executive Vice President, Operations
Ms. Habibizad joined GBT in January 2016 to help lead the company’s chemistry and manufacturing control (CMC) organization. She was promoted to executive vice president, operations in March 2022, where she is responsible for the manufacturing, global supply chain and logistics, and quality assurance functions. Under her direction and leadership, GBT successfully executed the CMC activities supporting the NDA submission, approval, launch and pediatric label expansion of Oxbryta® (voxelotor) in the United States, along with European Commission approval. Prior to GBT, she worked at Onyx Pharmaceuticals (acquired by Amgen), where she held roles of increasing responsibility, the most recent being senior director of CMC analytical. At Onyx, she played a critical role in the NDA submission, approval and global commercialization of Kyprolis. Prior to that, she held positions at Proteolix, Johnson & Johnson and Alza Corporation. Ms. Habibizad has particular expertise in CMC and a track record leading key activities and teams in product development from initial concept through commercialization across multiple global marketed products, including Concerta and Invega. She earned a B.S. in chemistry from the University of California, Berkeley.